VYLDA TAB

About

Vylda (Vildagliptin) is an oral anti-diabetic medication belonging to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, used for the management of type 2 diabetes mellitus. It works by inhibiting the enzyme DPP-4, which is responsible for the inactivation of incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By preserving active incretin levels, Vildagliptin enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses glucagon secretion from pancreatic alpha cells.

This dual action helps to lower both fasting and post-meal blood glucose concentrations without causing significant weight gain or a high risk of hypoglycemia when used as monotherapy. It is typically prescribed when diet and exercise alone are insufficient, and can be used alone or in combination with other anti-diabetic agents.

Uses

• Treatment of type 2 diabetes mellitus.
• Improving glycemic control.
• Reducing fasting and post-meal blood sugar.
• Used as monotherapy or in combination therapy.

Directions For Use

Take orally, usually once or twice daily, with or without food, as directed by your physician.

Benefits

• Effective in lowering blood glucose.
• Low risk of hypoglycemia as monotherapy.
• Weight-neutral effect.
• Improves both fasting and post-meal glucose.
• Enhances natural insulin release.
• Well-tolerated in most patients.

Side Effects

• Headache
• Dizziness
• Nausea
• Diarrhea
• Constipation
• Upper respiratory tract infection
• Nasopharyngitis
• Cough
• Peripheral edema
• Arthralgia (joint pain)
• Pancreatitis (rare)
• Liver enzyme elevation (rare)

Safety Measures

• Alcohol - Moderate alcohol consumption is generally acceptable, but excessive intake may affect blood sugar levels.
• Pregnancy - Vildagliptin is not recommended during pregnancy due to insufficient data on human safety. Insulin is usually preferred.
• Breastfeeding - It is advised to avoid Vildagliptin during breastfeeding as it may pass into breast milk. Consult a doctor.
• Liver - Vildagliptin is not recommended for patients with moderate to severe liver impairment due to potential for liver enzyme elevation.
• Kidney - Dose adjustment may be required in patients with moderate to severe kidney impairment. Consult your doctor.
• Lung - No specific contraindications or major safety concerns related to lung conditions are typically associated with Vildagliptin.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.